To examine the clinical efficacy of the anti-glutamatergic medication riluzole in posttraumatic stress disorder (PTSD), and its effect on hippocampus biomarkers that our laboratory previously has identified using MRS.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
20
30 PTSD patients with riluzole 100 mg daily (50 mg bid).
McLean Hospital
Belmont, Massachusetts, United States
Assessing the clinical efficacy of riluzole in PTSD
Testing the hypothesis that riluzole monotherapy will yield within-subject reductions in PTSD total symptoms (CAPS total score)
Time frame: weeks 1-8
Assessing the clinical efficacy of riluzole in PTSD
Testing the hypothesis that riluzole monotherapy will yield within-subject reductions in PTSD intrusion symptoms (CAPS intrusion subscale)
Time frame: weeks 1-8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.